CAS 950769-58-1
:Quizartinib
Description:
Quizartinib is a small molecule inhibitor primarily used in the treatment of acute myeloid leukemia (AML) with specific mutations in the FLT3 gene. It is classified as a tyrosine kinase inhibitor, targeting the FLT3 receptor, which is often mutated in AML, leading to uncontrolled cell proliferation. The chemical structure of Quizartinib includes a pyrimidine core, which is essential for its biological activity. It exhibits high selectivity for the FLT3 receptor, including both the wild-type and the most common activating mutations, making it a valuable therapeutic agent. Quizartinib is administered orally and has been evaluated in clinical trials for its efficacy and safety profile. Its pharmacokinetics indicate a moderate half-life, necessitating careful dosing regimens. Adverse effects may include hematological toxicities, gastrointestinal disturbances, and potential for QT interval prolongation. Overall, Quizartinib represents a targeted approach in the management of FLT3-mutated AML, contributing to advancements in personalized cancer therapy.
Formula:C29H32N6O4S
InChI:InChI=1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36)
InChI key:InChIKey=CVWXJKQAOSCOAB-UHFFFAOYSA-N
SMILES:O(CCN1CCOCC1)C=2C=C3C(N4C(S3)=NC(=C4)C5=CC=C(NC(NC=6C=C(C(C)(C)C)ON6)=O)C=C5)=CC2
Synonyms:- Ac 010220
- Ac-220
- N-(5-tert-Butylisoxazol-3-yl)-N'-[4-[7-[2-(morpholin-4-yl)ethoxy]imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea
- N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea
- N-[5-(1,1-Dimethylethyl)-3-isoxazolyl]-N′-[4-[7-[2-(4-morpholinyl)ethoxy]imidazo[2,1-b]benzothiazol-2-yl]phenyl]urea
- Quizartinib
- Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N′-[4-[7-[2-(4-morpholinyl)ethoxy]imidazo[2,1-b]benzothiazol-2-yl]phenyl]-
- N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea AC-220
- N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-Morpholin-4-ylethoxy)iMidazo[2,1-b][1,3]benzothiazol-2-yl]
- quizartinib (FLT3 inhibitor)
- AC220 (Quizartinib)
- 2-(4-AMinophenyl)-7-(2-Morpholin-4-yl-ethoxy)iMidazo[2,1-b]-[1,3]benzothiazole
- AC220 (Quizartinib, AC010220)
- 1-(5-(tert-butyl)isoxazol-3-yl)-3-(4-(7-(2-Morpholinoethoxy)benzo[d]iMidazo[2,1-b]thiazol-2-yl)phenyl)urea
- Quizartinib AC-220
- AC220, AC010220
- See more synonyms
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 8 products.
N-(5-tert-Butylisoxazol-3-yl)-N'-[4-[7-[2-(morpholin-4-yl)ethoxy]imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea
CAS:Formula:C29H32N6O4SPurity:98%Color and Shape:SolidMolecular weight:560.6672Ref: IN-DA003A8H
1g670.00€1mg30.00€5mg50.00€10mg53.00€50mg103.00€100mg135.00€250mg196.00€500mg254.00€Quizartinib
CAS:<p>Quizartinib</p>Purity:99%Color and Shape: off-white to beige solidMolecular weight:560.67g/molQuizartinib
CAS:<p>Quizartinib (AC220) is an inhibitor of FLT3 (Kd: 1.6 nM) and demonstrates high selectivity for FLT3 when tested against a panel of 227 additional kinases.</p>Formula:C29H32N6O4SPurity:98% - 99.42%Color and Shape:SolidMolecular weight:560.67Quizartinib
CAS:<p>Inhibitor of FLT3 receptor tyrosine kinases; anti-neoplastic</p>Formula:C29H32N6O4SPurity:Min. 95%Color and Shape:White PowderMolecular weight:560.67 g/molAC 220
CAS:Controlled Product<p>Applications AC 220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).<br>References Zarrinkar, P., et al.: Blood, 114, 2984 (2009); Sato, T., et al.: Blood, 117, 3286 (2011)<br></p>Formula:C29H32N6O4SColor and Shape:NeatMolecular weight:560.67






